Correlation Between 89bio and Apellis Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both 89bio and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 89bio and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between 89bio Inc and Apellis Pharmaceuticals, you can compare the effects of market volatilities on 89bio and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 89bio with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of 89bio and Apellis Pharmaceuticals.

Diversification Opportunities for 89bio and Apellis Pharmaceuticals

0.31

Correlation Coefficient

89bio  Apellis Pharmaceuticals

Weak diversification

The 3 months correlation between 89bio and Apellis is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding 89bio Inc and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and 89bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 89bio Inc are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of 89bio i.e., 89bio and Apellis Pharmaceuticals go up and down completely randomly.

Pair Corralation between 89bio and Apellis Pharmaceuticals

Given the investment horizon of 90 days 89bio Inc is expected to generate 0.91 times more return on investment than Apellis Pharmaceuticals. However, 89bio Inc is 1.1 times less risky than Apellis Pharmaceuticals. It trades about -0.03 of its potential returns per unit of risk. Apellis Pharmaceuticals is currently generating about -0.03 per unit of risk. If you would invest  2,017  in 89bio Inc on August 31, 2024 and sell it today you would lose (1,118) from holding 89bio Inc or give up 55.43% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

89bio Inc  vs.  Apellis Pharmaceuticals

89bio Inc

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in 89bio Inc are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady basic indicators, 89bio may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Apellis Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Apellis Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Pair Trading with 89bio and Apellis Pharmaceuticals

The main advantage of trading using opposite 89bio and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 89bio position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.

The idea behind 89bio Inc and Apellis Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.